2Q Revenues: $5.5 billion (-2%)
2Q Earnings: $1.4 billion (+6%)
YTD Revenues: $11.4 billion (+6%)
YTD Earnings: $2.9 billion (-48%)
Comments: Trulicity revenue was $1.2 billion, up 20% in the quarter, driven by increased demand, partially offset by lower realized prices. Humalog revenue decreased 18% to $555.1 million. Revenue in the U.S. decreased 29 driven primarily by lower realized prices, reflecting a favorable Medicaid adjustment in 2Q19 and an unfavorable Managed Care adjustment in the quarter. Alimta revenue decreased 7% to $539.1 million, primarily driven by decreased demand in the U.S. Taltz revenue increased 12% to $395.2 million driven by increased demand, partially offset by lower realized prices. Humulin revenue decreased 3% to $313.6 million. U.S. revenue decreased 3%, to $214.3 million, driven by lower realized prices due to changes in segment mix. Basaglar revenue was flat at $290.4 million. Jardiance revenue was $262.0 million, up 13% compared with 2Q19, driven by increased demand. Forteo revenue decreased 30% to $252.7 million. U.S. revenue decreased 31%, driven by lower demand and lower realized prices. Cyramza revenue was $256.7 million, up 6%, primarily driven by higher realized prices and increased demand. Acquired in-process R&D expenses were $241.8 million in the quarter associated with upfront payments related to both a business development transaction with a preclinical stage company as well as transactions with AbCellera Biologics Inc., Evox Therapeutics, and Junshi Biosciences.